The long-awaited ESMO Asia Congress is back again this year with special emphasis on the presentation and discussion of novel scientific and clinical advancements in the oncological domain in the Asia-Pacific region. DelveInsight’s team got the opportunity to attend and exhibit at the ESMO Asia Congress 2022 and mark its presence.
The DelveInsight team will get a golden networking opportunity to expand networks with industrial personnel globally. With more than 25,000 members representing oncology professionals from over 160 countries worldwide, ESMO creates a platform for learning and discussing current and future issues in the oncology domain.
Our professionals will get a chance to witness insightful meetings, oncology workshops, and note-worthy educational sessions on issues of particular relevance and importance to clinical oncologists and researchers. ESMO is a home for all oncology stakeholders connecting worldwide cancer specialists with unmatchable expertise and experience.
DelveInsight will acknowledge thousands of scientific abstracts being presented at the ESMO Congress based on the latest updates and findings from cancer clinical trials, including revolutionizing new drug studies and changing the perspective of cancer patient care. We also support ESMO’s notion of erasing boundaries in cancer care between countries and pursuing a united mission across oncology worldwide. We will incorporate these findings and the latest breakthroughs in our upcoming reports, which will help our clients to get an immense understanding of the future oncology domain.
Schedule A One-To-One Meeting with Our Delegates At ESMO Asia Congress 2022, from 2nd December 2022 to 4th December 2022.
Join us simply by filling up the form upright.
DelveInsight’s Oncology Portfolio Management services provide exceptionally unmatched assistance in understanding competencies in the oncology market. In addition to that, we prioritize strategic goals, assess the changes in the oncology industry, understand the current needs of the cancer market and likewise work on creating value for client services.
DelveInsight aims at providing effective reports that tally with the rare cancer market. Our analysts track developmental, regulatory & commercial milestones of competitor products. It includes aspects such as conference assessment, and company and R&D development assessment to carry out the desired development of oncological products for commercial purposes dealing with the client’s area of interest.
Our multidimensional, purposeful, and credible consultancy services will help in accelerating oncology product services, it includes aspects such as congress intelligence, conference coverage, CI asset/indication tracking, brand presence and penetration assessment, drug therapy uptake, diagnostic landscape assessment to overcome several challenges in the oncology market.
We have a specialized primary Competitive Intelligence research team that has expertise in the field of oncology. It constitutes analysts, senior analysts, and managers. Our CI force provides the best possible opportunities and most accurate intelligence that can be accumulated and provided to our partners. In addition, exceptionally well and a collection of cancer data with a fundamental goal of acquiring best-in-class intelligence and providing oncology analysis with respect to different cancer therapeutics to achieve the consultation goal of our partners.
Our research and development analyst understands the oncology realm to create value-based decisions and help clients achieve better oncological R&D endeavors. Any oncological drug's journey through pre-clinical and clinical development is done by assessing the same parameters of other candidates already in the space. DelveInsight’s insight-packed oncological reports provide clarity on uncertainties and challenge blind spots to provide timely intelligence to the company.
DelveInsight’s Oncological Pipeline Assessment promises an overarching view of cancer therapies, their clinical trials, as well as each and every highlight of the cancer therapeutics landscape in a report format. Encompassing oncology ready reports already present in our Report Store, our Pipeline Assessment report type provides insights across therapies, MoAs, Drugs, APIs, as well as Launch Insights of drugs in late-stage of development to provide an understanding of their launch timelines and strategies.
We welcome you to discuss your business-related concerns, and we can together find the best possible solution to help you proceed further in the Biotechnology and Pharma market.
Ms. Sadaf Javed is currently working in the Forecasting team with experience of almost 6 years in hand and expertise in creating indication-based pharma forecasting dynamic models. They include important categories such as disease epidemiology analysis, current market sales analysis, and upcoming market sizing estimations. An exceptionally skilled consultant, she is also involved in client interaction and has worked in several therapeutic areas including Neurological disorders, rare indications, autoimmune disorders, and Oncology. In addition to that, her responsibility extends by covering many International Oncology Conferences such as ASCO, and ESMO.
Rajesh is an extremely enthusiastic and dedicated professional who is self motivated, hard working and having decision making ability. With more than 10+ years of experience in market research having expertise in Market intelligence, BD&L, Strategic Planning and Forecasting. Throughout these years his major focus was Oncology and Rare Diseases space.
The ESMO Asia Congress 2022 conference and exhibition will take place in Singapore, Republic of Singapore, from December 2nd to 4th, 2022. Let’s connect!
